Hepatitis C

INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Also Known As:

Networked: 8387 relevant articles (512 outcomes, 785 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Infection
2.	Fibrosis (Cirrhosis)
3.	Hepatitis B
4.	Chronic Hepatitis C
5.	Hepatitis

Experts

1.	Forns, Xavier: 41 articles (01/2016 - 09/2003)
2.	Zeuzem, Stefan: 41 articles (10/2015 - 06/2003)
3.	Berg, Thomas: 35 articles (02/2016 - 08/2003)
4.	Wedemeyer, Heiner: 31 articles (02/2016 - 07/2004)
5.	Berenguer, Marina: 31 articles (09/2015 - 07/2002)
6.	Colombo, Massimo: 30 articles (09/2015 - 01/2003)
7.	Manns, Michael P: 29 articles (02/2016 - 01/2002)
8.	Spengler, Ulrich: 27 articles (02/2016 - 06/2002)
9.	Terrault, Norah A: 27 articles (11/2015 - 03/2004)
10.	McHutchison, John G: 26 articles (09/2015 - 02/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hepatitis C:

1.	InterferonsIBA 10/01/2007 - "Perhaps the most significant recent advance in this area is our improved understanding of the safety and efficacy of interferon-based antiviral therapies for children with hepatitis C. " 08/01/2002 - "To our knowledge, this is the first reported hepatitis C patient showing anti-RNP antibody and anti-SSB antibody, having complete remission after interferon therapy." 12/01/1996 - "Prediction of response to interferon therapy is important in the management of chronic hepatitis C. " 11/01/2007 - "Hepatitis C patients with stable psychiatric history can be successfully treated with interferon-based therapy if followed closely by a multidisciplinary team that includes specialists in hepatitis C and behavioral health." 03/01/2001 - "Results of Phase II/III hepatitis C clinical trials in humans confirmed the superior efficacy of pegylated interferon alpha-2a compared to unmodified interferon alpha-2a."
2.	Ribavirin (Virazole)FDA LinkGeneric 11/01/2002 - "Thus, the combination of peginterferon and ribavirin was the most efficacious treatment in patients with HCV genotype 1. Long-term outcomes were improved in patients with hepatitis C who achieved an SVR with treatment." 01/01/2002 - "The substituted IFN had an enhanced pharmacokinetic profile in both animal and human studies, and, when combined with ribavirin, was very effective in reducing hepatitis C viral load and maintaining sustained viral suppression in patients." 02/01/2009 - "Ribavirin: current role in the optimal clinical management of chronic hepatitis C." 05/01/2005 - "Nonetheless, there are now data to support the safety, tolerability and efficacy of hepatitis C treatment with peginterferon plus ribavirin in HIV-infected patients, and the impetus to treat these patients is, therefore, strong. " 01/01/2012 - "The aim of this study was to document in real life the characteristics and management of hepatitis C patients treated with pegylated interferon-α2a and ribavirin, and the efficacy of treatment (sustained virological response [SVR]). "
3.	Interferon-alpha (Interferon Alfa)FDA Link 01/01/2002 - "Interferon alfa is effective in improving biochemical outcomes and achieving sustained virologic clearance in patients with transfusion-acquired acute hepatitis C. " 09/01/1999 - "The results of controlled trials have shown that interferon alpha is an effective treatment for hepatitis C. " 12/01/2011 - "Interferon-alfa-based therapy is effective in the treatment of Hepatitis C. " 01/01/2009 - "Does antidepressant medication in patients with hepatitis C undergoing interferon alpha treatment reduce therapeutic efficacy?" 05/01/1993 - "Interferon-alpha is the only approved and effective treatment for hepatitis C. "
4.	RNA (Ribonucleic Acid)IBA 07/01/1994 - "This study reveal that IFN therapy for acute hepatitis C may contribute to prevent the progression to chronicity and that the determination of the level of serum HCV RNA, HCV genotypes and anti C 100-3 levels may be useful to predict that efficacy of IFN and also to make a schedule for successful IFN therapy." 01/01/1999 - "In conclusion, the search for HCV RNA by RT-PCR within the liver biopsy specimen can establish rapid and unequivocal diagnosis of hepatitis C in at least 60% of anti-HCV antibody-positive patients who are seronegative for HCV RNA, and thus may help to avoid repeated testing and delayed therapy. " 04/01/2013 - "Accurate hepatitis C virus (HCV) RNA quantification is mandatory for the management of chronic hepatitis C therapy. " 01/01/2012 - "The gold standard for the diagnosis of acute hepatitis C is demonstration of conversion to anti-HCV positivity, HCV RNA positivity or both, events that frequently occur before the patient comes to medical attention. " 11/01/2009 - "The gold standard for the diagnosis of acute hepatitis C (AHC) is seroconversion to anti-HCV/HCV-RNA positivity, an occurrence frequently missed in clinical practice. "
5.	Antiviral Agents (Antivirals)IBA 10/28/2013 - "Step by step the efficacy of the therapy for hepatitis C is rapidly increasing and nowadays with the very new medications, the so called Direct Antiviral Agents-DAAs of new generation, is around 80%-90%." 01/01/2015 - "Within the past years, direct-acting antivirals (DAAs) have had a major impact on the management of chronic hepatitis C, which has become a curable disease in the majority of DAA-treated patients. " 10/01/2015 - "The presence of resistance-associated variants (RAV) may attenuate the efficacy of direct-acting antivirals (DAA) in combination therapy for hepatitis C. " 03/01/2015 - "IFN-free regimens with direct antiviral agents (DAAs) against hepatitis C virus (HCV) are likely to greatly expand patients' access and response to hepatitis C therapy, while safety and tolerability of treatments seem substantially improved. " 06/01/2014 - "To increase efficacy of hepatitis C treatment, future regiments will incorporate multiple direct-acting antiviral drugs. "
6.	Protease Inhibitors (Protease Inhibitor)IBA 01/01/2015 - "The first generation protease inhibitors has been the mainstay of hepatitis C treatment for the last couple of years, showing marked improvement in sustained virological response, but also increased side effects. " 10/01/2014 - "With the introduction of the first-generation protease inhibitors the efficacy of hepatitis C treatment improved significantly. " 03/01/2013 - "An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver." 01/01/2013 - "A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients." 11/01/2015 - "Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake."
7.	telaprevirIBA 12/01/2014 - "A significantly greater proportion of patients were persistent to the 3-drug hepatitis C regimen containing telaprevir in specialty pharmacy, compared with retail pharmacy (56.0% vs. 39.9%, P  less than  0.001). " 11/18/2015 - "To investigate the efficacy of virological response (VR) to telaprevir (TVR)-based triple therapy in predicting treatment outcome of hepatitis C. " 04/01/2015 - "Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy." 01/01/2013 - "This article briefly reviews the properties of telaprevir and its status in the context of rapidly evolving aspects of management of chronic hepatitis C." 12/01/2014 - "Continuously eligible patients who started a new 3-drug regimen containing telaprevir were included in the study and followed for up to 12 months after the index hepatitis C claim. "
8.	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 03/01/2013 - "Boceprevir represents a new treatment option for hepatitis C (HCV)-infected patients, including those with HCV/human immunodeficiency virus coinfection; however, little is known about pharmacokinetic interactions between boceprevir and antiretroviral drugs. " 01/01/2013 - "The boceprevir-based regimens used in the SPRINT-2 trial were projected to substantially reduce the lifetime incidence of liver complications and increase the QALYs in treatment-naive patients with hepatitis C genotype 1. It was also demonstrated that boceprevir-based regimens offer patients the possibility of experiencing great clinical benefit with a shorter duration of therapy. " 10/01/2015 - "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease." 01/01/2015 - "Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations." 10/01/2014 - "Predicting the probability of experiencing clinically significant drug-drug interactions involving boceprevir-containing hepatitis C therapy among patients coinfected with hepatitis C and HIV."
9.	Carbon MonoxideIBA 01/01/2004 - "My personal experience in being HCV/HIV co-infected & how I cured hepatitis C." 01/01/2004 - "Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations." 01/01/2015 - "An Aggravated Trajectory of Depression and Anxiety Co-morbid with Hepatitis C: A Within-groups Study of 61 Australian Outpatients." 01/01/2011 - "The unfulfilled promise of efficacy trials in HIV/hepatitis C co-infected patients." 08/24/2010 - "A total of 184 HIV/HCV co-infected Caucasian patients were enrolled into this study, including 109 patients with chronic and 75 patients with acute hepatitis C. "
10.	Viral RNAIBA 02/01/2013 - "Hepatitis C virus (HCV) RNA viral load (VL) monitoring is a well-established diagnostic tool for the management of chronic hepatitis C patients. " 01/01/2014 - "In this study, we combine available high resolution structural information on eukaryotic ribosomes with low resolution cryo-EM data on the Hepatitis C Viral RNA (IRES) human ribosome complex. " 11/25/2013 - "Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design." 06/01/2005 - "This study was conducted to determine the optimal dosing regimen of PEG-IFN-alfa 2b required to obtain a maximum decrease of hepatitis C viral RNA. " 01/01/2015 - "Competitive binding between miR-122 and p68 onto hepatitis C viral RNA."

Therapies and Procedures

1.	Liver Transplantation 05/01/2015 - "Spontaneous clearance of hepatitis C rarely occurs after liver transplantation and is extremely rare after retransplantation. " 06/01/2013 - "The efficacy of antiviral therapy in patients with hepatitis C recurrence after liver transplantation (LT) is far from optimal and a careful selection of candidates with the best chances to achieve sustained virological response (SVR) is relevant. " 04/01/2015 - "Although careful monitoring for possible adverse events is required during treatment, triple therapy with the use of direct-acting agents are very effective in treating hepatitis C after liver transplantation." 10/01/2002 - "1. Primary orthotopic liver transplantation (OLT) for hepatitis C is performed with good results. " 09/01/2014 - "Appropriate antiviral treatment is essential for living donor liver transplantation (LDLT) to be effective for treating hepatitis C. "
2.	Transplants (Transplant) 11/01/2002 - "Transfusions and transplants have been virtually eliminated as sources for transmission, and most (68%) newly acquired cases of hepatitis C are related to injecting drug use. " 01/01/2015 - "Although some scholars believed that liver transplant using elderly grafts was associated with high probability of delayed liver function recovery, graft loss and hepatitis C recurrence, reports from several transplant centers document that long-term survival of grafts and recipients may be significantly improved through certain screening of donors and recipients before transplant. " 05/01/2014 - "For patients with hepatitis C, transplant (n = 87) demonstrated significantly improved 5-year outcomes compared to patients meeting MC who underwent resection (n = 21; OS: 63.5% vs. 23.3%; P = 0.001; RFS: 83.5% vs. 23.7%; P < 0.001). " 02/01/2010 - "Minimal but significant improvement in survival for non-hepatitis C-related adult liver transplant patients beyond the one-year posttransplant mark." 11/01/2015 - "Hepatitis C was eradicated, and the patient was removed from the transplant list. "
3.	Transplantation (Transplant Recipients) 06/01/2009 - "Use of rapid and early virological responses is very helpful in the management of hepatitis C after transplantation. " 06/01/2006 - "We conclude that hepatitis C prevented improved outcomes during period II and that improved, more effective, treatment for hepatitis C virus would have great positive impact on overall survival of liver transplant recipients." 11/01/2015 - "Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients." 01/01/2005 - "The results of this preliminary study suggest that posttransplant monitoring of the frequency of donor-specific IFN-gamma-producing precursors may differentiate a subset of patients at risk for early recurrent hepatitis C and therefore may help to devise treatment strategies for HCV+ liver recipient after transplantation." 12/01/2014 - "In liver transplant recipients with genotype 1 hepatitis C, success rates in the same range can be expected after 24 weeks of treatment according to preliminary trial results. "
4.	Renal Dialysis (Hemodialysis) 09/01/2010 - "From 2005 through 2008, 35 hemodialysis patients with acute hepatitis C who did not have spontaneous clearance of HCV by 16 weeks were treated with pegylated IFN alfa-2a at a dosage of 135 microg weekly for 24 weeks. " 11/01/2014 - "Study molecular epidemiology of hepatitis C (HC) in 5 departments of hemodialysis (DH) in St. Petersburg. " 10/01/2013 - "The findings of this study highlight the importance of control strategies for hepatitis C in hemodialysis patients. " 12/01/2010 - "This study aimed at assessing the influence of hepatitis C on the mortality of patients undergoing hemodialysis. " 01/01/2007 - "The aim of this study was analyze the follow up of newly acquired acute hepatitis C cases, during the period from January 2002 to May 2005, in the Hemodialysis Center, located in the Southwest region of Parana State, Brazil and to analyze the effectiveness of the measures to restrain the appearance of new cases of acute hepatitis C. "
5.	Homologous Transplantation (Allograft) 11/01/2014 - "In view of the risk of rejection of renal allograft, and the limited efficacy of IFN-based treatment of hepatitis C, physicians should be aware of effective treatment with oral anti-viral agents and avoid the use of IFN in patients on maintenance dialysis with failed renal allograft. " 12/01/2015 - "Re: Shorter Waitlist Times and Improved Graft Survivals are Observed in Patients Who Accept Hepatitis C Virus+ Renal Allografts." 06/01/2015 - "Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts." 11/01/2000 - "Liver biopsy specimens are helpful for the diagnosis or confirmation of early recurrent hepatitis C in liver allografts, but serial biopsy specimens are sometimes required for definite diagnosis. " 07/01/2003 - "We report the results of a large monocenter study that evaluated the effect of hepatitis C on the patient, and on graft survival in renal-transplanted patients who received living donated allograft. "